Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: The 2022 update. Eur Urol. 2022;82:399–410.

Article  PubMed  Google Scholar 

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.

Article  CAS  PubMed  Google Scholar 

Tran J, Ornstein MC. Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract. 2022;18:187–96.

Article  PubMed  Google Scholar 

Dudani S, de Velasco G, Wells C, Gan CL, Donskov F, Porta C, et al. Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC database consortium (IMDC). JCO. 2020;38:642–642.

Article  Google Scholar 

Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. The Lancet. 1999;353:14–7.

Article  Google Scholar 

Powles T, Albiges L, Bex A, Comperat E, Grünwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692–706.

Article  CAS  PubMed  Google Scholar 

Chen Y-W, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, et al. Treatment landscape of renal cell carcinoma. Curr Treat Options Oncol. 2023;24:1889–916.

Article  PubMed  PubMed Central  Google Scholar 

Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18:199–214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, et al. Management of metastatic clear cell renal cell carcinoma: asco guideline. J Clin Oncol. 2022;40:2957–95.

Article  CAS  PubMed  Google Scholar 

Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Bekku K, et al. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data. Cancer Immunol Immunother. 2024;73:38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, et al. First-line Immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. European Urology Oncology. 2021;4:755–65.

Article  PubMed  Google Scholar 

Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–300.

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1103–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024;35:1026–38.

Article  CAS  PubMed  Google Scholar 

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open [Internet]. 2020 [cited 2025 Mar 7];5. Available from: https://www.esmoopen.com/article/S2059-7029(20)32764-2/fulltext

Moinard-Butot F, Oriel M, Tricard T, Cazzato RL, Pierard L, Gaillard V, et al. Effect of treatment of residual disease after immunotherapy-based combinations on complete response rate of patients with metastatic renal cell carcinomas. Clin Genitourin Cancer. 2024;22: 102134.

Article  CAS  PubMed  Google Scholar 

Albiges L, Gross-Goupil M, Barthélémy P, Bamias A, Bedke J, Bex A, et al. Towards a consensus on the management of metastatic renal cell carcinoma: insights from a european delphi study. Eur Urol Oncol. 2025;S2588–9311(25):00028–38.

Google Scholar 

Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, Fernandez LG, Neyt M, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41:1189–204.

Article  PubMed  PubMed Central  Google Scholar 

de Baere T. Growing evidence for percutaneous thermal ablation of lung metastases: long-term data are needed to allow for comparison with other local treatments. Cardiovasc Intervent Radiol. 2022;45:1755–6.

Article  PubMed  Google Scholar 

Pan S, Baal JD, Chen WC, Baal U, Pai JS, Baal JH, et al. Image-guided percutaneous ablation of adrenal metastases: a meta-analysis of efficacy and safety. J Vasc Interv Radiol. 2021;32:527-535.e1.

Article  PubMed  Google Scholar 

Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197:44–9.

Article  PubMed  Google Scholar 

Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, et al. Complications after metastasectomy for renal cell carcinoma-a population-based assessment. Eur Urol. 2017;72:171–4.

Article  PubMed  Google Scholar 

Lehrer R, Cornelis F, Bernhard J-C, Bigot P, Champy C, Bruyère F, et al. Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation. Eur Radiol. 2023;33:8426–35.

Article  PubMed  Google Scholar 

Meijerink MR, van der Lei S, Dijkstra M, Versteeg KS, Buffart TE, Lissenberg-Witte BI, et al. Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. JCO. 2024;42:3501–3501.

Article  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681–93.

Article  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell Carcinoma. N Engl J Med. 2021;385:683–94.

Article  CAS  PubMed  Google Scholar 

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17:1317–24.

Article  PubMed  PubMed Central  Google Scholar 

Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, et al. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014;192:357–63.

Article  PubMed  Google Scholar 

Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol. 2012;23(6):770–777. https://doi.org/10.1016/j.jvir.2012.03.002.

Article  Google Scholar 

Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, et al. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021;12:6375.

Article  CAS  PubMed  PubMed Central